Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PALI
Upturn stock ratingUpturn stock rating

Palisade Bio Inc (PALI)

Upturn stock ratingUpturn stock rating
$0.68
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: PALI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $10.67

1 Year Target Price $10.67

Analysts Price Target For last 52 week
$10.67Target price
Low$0.6
Current$0.68
high$4.89

Analysis of Past Performance

Type Stock
Historic Profit -70.24%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.50M USD
Price to earnings Ratio -
1Y Target Price 10.67
Price to earnings Ratio -
1Y Target Price 10.67
Volume (30-day avg) 3
Beta 1.34
52 Weeks Range 0.60 - 4.89
Updated Date 06/30/2025
52 Weeks Range 0.60 - 4.89
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.07

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -80.94%
Return on Equity (TTM) -170.72%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3673048
Price to Sales(TTM) 14.03
Enterprise Value -3673048
Price to Sales(TTM) 14.03
Enterprise Value to Revenue 234.89
Enterprise Value to EBITDA 0.57
Shares Outstanding 4795650
Shares Floating 4301790
Shares Outstanding 4795650
Shares Floating 4301790
Percent Insiders 0.46
Percent Institutions 5.43

Analyst Ratings

Rating 2
Target Price 10.67
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Palisade Bio Inc

stock logo

Company Overview

overview logo History and Background

Palisade Bio, Inc. (formerly Seneca Biopharma, Inc.), founded in 2008, is a biopharmaceutical company focused on developing novel therapeutics for indications impacting the gastrointestinal (GI) system.

business area logo Core Business Areas

  • Lead Asset Development: Development of LB1148, a novel oral formulation of a protease inhibitor, for accelerating the return of bowel function following surgery.

leadership logo Leadership and Structure

The leadership team is led by Darlene M. Conley, M.D., as Chief Executive Officer. The organizational structure comprises research and development, clinical operations, and corporate administration departments.

Top Products and Market Share

overview logo Key Offerings

  • LB1148: LB1148 is Palisade Bio's lead product candidate designed to neutralize digestive enzymes, potentially speeding up the return of bowel function post-surgery. Market share is currently 0% as it is in clinical development. Competitors include current standard of care like supportive care and potentially future competing therapies targeting post-operative ileus (POI).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is continuously innovating in drug development and clinical applications. There is a demand for better treatments for GI-related conditions and post-operative care.

Positioning

Palisade Bio is positioned to address a significant unmet need in accelerating the return of bowel function post-surgery. Its competitive advantage lies in the novel mechanism of action of LB1148.

Total Addressable Market (TAM)

The TAM for therapies addressing post-operative ileus is estimated to be in the hundreds of millions of dollars annually. Palisade Bio is aiming to capture a significant portion of this market with LB1148.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach (LB1148)
  • Experienced management team
  • Targeting a significant unmet medical need

Weaknesses

  • Reliance on a single lead product candidate
  • Limited financial resources
  • Clinical and regulatory risks

Opportunities

  • Successful clinical trials and regulatory approval of LB1148
  • Partnerships with larger pharmaceutical companies
  • Expansion into additional GI indications

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from existing and emerging therapies

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Palisade Bio's competitive advantage lies in LB1148's novel mechanism. The competitive landscape includes supportive care methods, other pharmaceutical interventions targeting ileus or bowel obstruction.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is minimal as the company is focused on drug development and has not yet launched a commercial product.

Future Projections: Future growth depends on the successful development and commercialization of LB1148 and potential expansion into other GI indications.

Recent Initiatives: Recent initiatives include advancing LB1148 through clinical trials and seeking strategic partnerships.

Summary

Palisade Bio is a biopharmaceutical company with a promising lead product candidate, LB1148, targeting a significant unmet need in post-operative ileus. Its success hinges on the successful completion of clinical trials and securing regulatory approval. The company faces inherent risks associated with drug development, including potential clinical trial failures and regulatory hurdles. Palisade Bio needs to closely manage its cash flow and explore opportunities for partnerships to mitigate financial risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Press Releases

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Palisade Bio Inc

Exchange NASDAQ
Headquaters Carlsbad, CA, United States
IPO Launch date 2006-12-20
CEO, CFO & Director Mr. J. D. Finley
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.